Entrada stock falls on Duchenne data; Wegovy expands access

AI Summary

Entrada's stock has fallen due to disappointing data related to Duchenne muscular dystrophy treatment results, while the expansion of Wegovy program aims to increase access to obesity treatment. The dual narrative highlights challenges in the healthcare sector.